Johnson & Johnson (NYSE:JNJ) Stock Holdings Lessened by Simplify Asset Management Inc.

Simplify Asset Management Inc. trimmed its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 36.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 43,013 shares of the company's stock after selling 24,588 shares during the quarter. Johnson & Johnson comprises about 0.3% of Simplify Asset Management Inc.'s holdings, making the stock its 20th biggest position. Simplify Asset Management Inc.'s holdings in Johnson & Johnson were worth $6,221,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the stock. MRP Capital Investments LLC boosted its position in shares of Johnson & Johnson by 4.1% during the 4th quarter. MRP Capital Investments LLC now owns 1,640 shares of the company's stock worth $237,000 after acquiring an additional 65 shares in the last quarter. Werba Rubin Papier Wealth Management raised its stake in shares of Johnson & Johnson by 3.3% during the fourth quarter. Werba Rubin Papier Wealth Management now owns 2,080 shares of the company's stock worth $301,000 after purchasing an additional 66 shares during the last quarter. Denali Advisors LLC increased its stake in shares of Johnson & Johnson by 1.3% during the fourth quarter. Denali Advisors LLC now owns 5,128 shares of the company's stock worth $742,000 after acquiring an additional 67 shares during the period. Sage Mountain Advisors LLC raised its stake in shares of Johnson & Johnson by 0.5% during the 4th quarter. Sage Mountain Advisors LLC now owns 14,564 shares of the company's stock worth $2,106,000 after buying an additional 67 shares in the last quarter. Finally, Corepath Wealth Partners LLC grew its position in Johnson & Johnson by 3.7% during the fourth quarter. Corepath Wealth Partners LLC now owns 1,985 shares of the company's stock worth $287,000 after buying an additional 70 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.

Remove Ads

Analyst Ratings Changes

JNJ has been the subject of several analyst reports. Barclays boosted their target price on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an "equal weight" rating in a research note on Tuesday, January 28th. Citigroup reduced their target price on Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating on the stock in a report on Wednesday, December 11th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, February 19th. Wells Fargo & Company dropped their target price on shares of Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating for the company in a research report on Thursday, January 23rd. Finally, Morgan Stanley reduced their target price on shares of Johnson & Johnson from $175.00 to $163.00 and set an "equal weight" rating on the stock in a report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and a consensus target price of $171.33.

Insider Transactions at Johnson & Johnson

In related news, EVP Timothy Schmid sold 403 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares of the company's stock, valued at $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Performance

NYSE:JNJ traded down $1.29 during trading hours on Tuesday, reaching $162.00. 1,965,556 shares of the stock were exchanged, compared to its average volume of 7,088,162. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The firm has a 50 day simple moving average of $157.37 and a 200-day simple moving average of $156.16. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $390.40 billion, a P/E ratio of 24.35, a P/E/G ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business's revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.29 EPS. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.06%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson's payout ratio is currently 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.